Skip to main content
Article thumbnail
Location of Repository

Personalizing Health Care—Is This the Right Time for Warfarin?

By Jack Ansell
Topics: Editorial
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2669875
Provided by: PubMed Central

Suggested articles

Citations

  1. Clinicaltrials.gov identifier: NCT00839657 691 Ansell: Personalizing Health Care-Is This the Right Time for Warfarin?
  2. (2009). Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med.
  3. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel.
  4. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
  5. (2009). Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.
  6. (2009). Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA.
  7. (2004). Identification of the gene for vitamin K epoxide reductase.
  8. (2003). Inheritance and drug response.
  9. (2008). Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost.
  10. (2009). Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data.
  11. (2008). Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis.
  12. (2009). Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?
  13. (2008). The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. Chest.
  14. (2004). The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy-a decision analysis. Thromb Haemost.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.